| Literature DB >> 28858248 |
Mariana Novo Belchor1,2, Henrique Hessel Gaeta3, Caroline Fabri Bittencourt Rodrigues4, Caroline Ramos da Cruz Costa5, Daniela de Oliveira Toyama6, Luiz Felipe Domingues Passero7, Marcia Dalastra Laurenti8, Marcos Hikari Toyama9.
Abstract
Rhamnetin (Rhm), 3-O-methylquercetin (3MQ), and Rhamnazin (Rhz) are methylated derivatives of quercetin commonly found in fruits and vegetables that possess antioxidant and anti-inflammatory properties. Phospholipase A2 (PLA2) displays several important roles during acute inflammation; therefore, this study aimed at investigating new compounds able to inhibit this enzyme, besides evaluating creatine kinase (CK) levels and citotoxicity. Methylated quercetins were compared with quercetin (Q) and were incubated with secretory PLA2 (sPLA2) from Bothrops jararacussu to determine their inhibitory activity. Cytotoxic studies were performed by using the J774 cell lineage incubated with quercertins. In vivo tests were performed with Swiss female mice to evaluate decreasing paw edema potential and compounds' CK levels. Structural modifications on sPLA2 were made with circular dichroism (CD). Despite Q and Rhz showing greater enzymatic inhibitory potential, high CK was observed. Rhm exhibited sPLA2 inhibitory potential, no toxicity and, remarkably, it decreased CK levels. The presence of 3OH on the C-ring of Rhm may contribute to both its anti-inflammatory and enzymatic inhibition of sPLA2, and the methylation of ring A may provide the increase in cell viability and low CK level induced by sPLA2. These results showed that Rhm can be a candidate as a natural compound for the development of new anti-inflammatory drugs.Entities:
Keywords: Bothrops jararacussu; anti-inflammatory; methylated quercetins; phospholipase A2; rhamnetin
Mesh:
Substances:
Year: 2017 PMID: 28858248 PMCID: PMC6151830 DOI: 10.3390/molecules22091441
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1sPLA2 purity profile by high-performance liquid chromatography (HPLC). The enzyme purification was performed with a TSKgel SP-5PW (7.5 cm ID × 7.5 cm·L) using a non-linear gradient with buffer B (ammonium bicarbonate 1.0 M) at a constant flow rate of 1.0 mL/min. The active sPLA2 underwent a new chromatographic step on a reverse phase HPLC using a C5 semi-analytical column. In this step, the chromatographic column was pre-equilibrated with buffer A (0.1% TFA) for 30 min at a flow rate of 1 mL/min. Samples of sPLA2 (1 mg) were dissolved in 250 μL of buffer A and separated using the chromatographic column. Elution of the sPLA2 was performed with a continuous linear gradient of buffer B (66% acetonitrile in 0.1% TFA), and the monitoring of the chromatographic profile was at 280 nm.
Figure 2Structures of the quercetins assayed with the enzymatic, circular dichroism, edema, creatine kinase levels, and cytotoxic assays. (A) The structures of all flavonols assayed here and R1, R2, and R3 indicated the principal substituents found in all of the flavonols; (B) The effect of the previous treatment of the sPLA2 samples on the enzymatic activity after 30 min compared with native sPLA2. 3MQ, Rhm, Rhz, and Q. Each column represents the mean and SD of six replicates (n = 6), and the asterisk (*) means p < 0.05; (C) CD spectra of isolated sPLA2 (saline) and all quercetins incubated with the enzyme. Data over the range of 190–280 nm are shown and are expressed in theta machine units in molar ellipticity (θ cm²/dmols), and each spectrum represents the analysis of three CD runs; (D) Graphic of the edema performed after 30 min of administration of the four quercetins evaluated (10 μg protein and 12.5 μg compound). The results are expressed as the mean ± standard deviation (n = 5), and the * means p < 0.05. We used the ANOVA and Bonferroni a posteriori tests; (E) Myotoxic activity of native and pretreated sPLA2 via measurement of the creatine kinase assay. Each column is shown as the mean and SD of n = 5 for each sample including saline, and ANOVA was used as the statistic assay with Dunnett as the a posteriori test. The * shows groups with significant differences with sPLA2 (p < 0.05); (F) To evaluate the cytotoxic potential of all compounds, MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay was performed with the J774 macrophages. Cells were incubated previously with each compound, and each point in the cell viability graph represents the mean and SD of 12 experiments.
Variation of the α-helix and β-sheet percentages in sPLA2 and in the quercetins incubated with the protein.
| sPLA2 | 3MQ | Rhm | Rhz | Q | |
|---|---|---|---|---|---|
| α-helix | 45.30% | 26.80% | 27.00% | 54.70% | 23.40% |
| β-sheet | 14.80% | 18.30% | 18.00% | 13.40% | 18.80% |
Figure 3Structure-function relation between molecular regions of Rhm and its activities. (A) Molecular structure of Rhm in which the 3-OH in the C ring should lead to enzymatic and pharmacological inhibition and OCH3 in the A ring should lead to cytotoxic and myotoxic protection; (B) Flavonol injection after 10 min of sPLA2 application (10 μg protein and 12.5 μg compound). The results are expressed as the mean ± standard deviation (n = 5), and the * means p < 0.05 using the ANOVA and Bonferroni a posteriori tests.